Linda Huguelet

Diagnosed with multiple myeloma in April 2010 at the young age of 46, Linda Huguelet has been co-leading the Chattanooga Multiple Myeloma Networking group alongside her husband since February 2011. She underwent an autologous stem cell transplant in 2010 and enjoyed almost four years in remission before her first relapse in 2014. She repeated her induction therapy of Revlimid®/Velcade/Dex and returned to a complete remission and continued treatment with Velcade maintenance. In May 2016, her numbers began to climb again and she maintained a VGPR with Empliciti®/Revlimid/Dex for almost 2 years. She is currently responding well to Darzalex®/Pomalyst®/Dex and enjoys only going for treatments on a monthly basis.

Linda has found it important to exercise regularly throughout her myeloma journey. She currently enjoys morning walks, tai chi and water aerobics. Fitness helps her mentally and physically which allows her to continue working full-time. She feels fortunate to be able to work remotely during her infusions.

Excited to learn of the latest developments in myeloma care, Linda will be attending ASH for the seventh time with the IMF. Updates on new combinations with the approved monoclonal antibodies and new emerging conjugated monoclonal antibody treatments will be of interest to Linda at this year’s ASH.

Follow Linda on Twitter

WOW – What an ASH!

Linda Huguelet |

The American Society of Hematology 62nd Annual Conference (ASH) was like none other in many ways. It was the first virtual meeting which certainly had its positives and negatives. It was much easier to take notes and I loved the ability to “rewind” the presentations to hear something for a second time. On the negative […]

Complicated Is A Good Thing

Linda Huguelet |

After finishing two full days of watching abstracts and education sessions about multiple myeloma at the American Society of Hematology Conference (ASH), my head is spinning from the number of new combinations, therapies, and therapy targets. All of this is excellent news for us, but this makes treatment decisions much more complicated. This diagram presented by Dr. […]

Exciting and Hopeful Studies at ASH 2020

Linda Huguelet |

Thanks to my dexamethasone today, I’m writing this in the wee hours of Saturday morning, and the All-Virtual 62nd American Society of Hematology (ASH) Meeting and Exposition kicks off in and few hours. It will include many abstracts (research presentations) about the future of multiple myeloma treatments. But even before ASH begins, the International Myeloma […]

2020 Marks 10 Years for Me

Linda Huguelet |

2020 has been an unprecedented year in many ways and there have been multiple hardships, but there have also been many positives for me. In April, I celebrated my ten-year anniversary since my multiple myeloma diagnosis, and in August my ten-year “birthday” since my autologous stem cell transplant! When I was diagnosed in 2010, reaching […]